MedTrace Logo

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

NCT00231790 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 848

Last updated 2015-12-17

No results posted yet for this study

Summary

Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.

Conditions

Interventions

DRUG

MK-0634 50 mg

one capsule orally, once daily in morning

DRUG

MK-0634 125 mg

one or three capsules orally, once daily in morning

DRUG

Placebo for MK-0634

one, two, three or four capsules orally once daily in morning

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-09-30
Completion
2006-10-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00231790 on ClinicalTrials.gov